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vided. At first, the BeLieVeR-HIFi study, a sham-con-
trolled, randomized trial of EBV treatment, where visual 
assessment of fissure integrity by CT scan was used to se-
lect patients, showed a significant benefit in favor of EBV 
treatment over control  [6] . However, post hoc analysis re-
vealed that if the Chartis system (which was performed in 
this trail) had been used to select the patients, the outcome 
would have been significantly better. Second, Schuhmann 
et al.  [7]  reported a response rate of 65% to EBV treatment 
if the fissure was >90% on CT. Nevertheless, this means 
that there is a significant proportion of patients without 
response. Finally, Klooster et al.  [1]  showed the real value 
of both the EBV treatment and optimal patient selection 
for this treatment. In the STELVIO trial, a randomized 
controlled trial to compare EBV treatment with standard 
medical care, CT scan was used to preselect potential can-
didates, but the Chartis assessment determined whether 
the patients were included in the trial. In the STELVIO 
trial, the EBV group improved very significantly in FEV 1 
(+22.7%) and 6MWD (106 m) compared to the control 
group. Based on this data, the Chartis system should be 
recommended to optimize treatment outcome, and thus 
avoiding unnecessary and costly treatment.
 The article by Herzog et al.  [8] published in a recent 
issue of  Respiration is a further step in improving the use 
of the Chartis system. The paper elegantly describes the 
 Bronchoscopic lung volume reduction using one-way 
endobronchial valves (EBV) for patients with severe em-
physema is evolving into a guideline therapy for this pa-
tient group  [1] . The elegance of this invasive broncho-
scopic intervention consists in the fact that responders to 
this treatment can nowadays be very accurately selected: a 
great example of precision medicine. From the VENT 
study, we have already learned the importance of both a 
full lobar treatment with and technically successful place-
ment of EBV as well as fissure completeness being a key to 
EBV treatment success  [2] . The VENT trial showed that 
we needed a tool which could prospectively evaluate the 
suitability of the individual patient for EBV treatment. To 
do this, both a very vigorous analysis of the interlobar fis-
sure on a thin-slice computed tomography (CT) of the 
thorax  [3] or using an effective functional measurement 
of the interlobar collateral flow  [4] are possible options.
 The multicenter European Chartis trial validated the 
use of the Chartis system, a bronchoscopic catheter-based 
system that can accurately measure, in real-time, the in-
terlobar collateral flow between the treatment target lobe 
and the adjacent lobe  [5] . This trial also showed similar 
predictive values for both CT fissure analysis or the Char-
tis system  [5] . So, to be able to identify our responders, do 
we need CT or Chartis, or maybe both? A direction to-
wards an answer to this question has recently been pro-
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collateral flow pattern ‘phenotypes’ that can be encoun-
tered during the assessment, thereby serving as a guid-
ance to everyone using this technique. The correct inter-
pretation of the Chartis findings is the key to success in 
EBV treatment. Performing the Chartis procedure in ex-
perienced hands is feasible and on average takes 10 min 
of procedure time, with less than 5% of indeterminable 
results. The procedure is easier and more reproducible in 
ventilated patients under general anesthesia, but can be 
more challenging with spontaneously breathing patients 
under minimal conscious sedation. Herzog et al.  [8] ob-
served four phenotypes: (1) collateral ventilation positive 
(persistent expiratory flow and no increase in the resis-
tance index over 5 min), (2) collateral ventilation negative 
(steady decline in expiratory flow with a corresponding 
increase in the resistance index), (3) low flow pattern 
(rapid decline in expiratory flow and increase in the resis-
tance index within 30 s of the onset of measurement and 
with less than 100 ml/s expired in total), and (4) low pla-
teau pattern (decrease in expiratory flow which then pla-
teaus and absence of a significant increase in the resis-
tance index over 5 min). The low flow phenotype is pre-
dominantly observed in the lower lobes and may be 
secondary to dynamic airway collapse; hence, further 
evaluation of the ipsilateral lobe may be of value. Other 
pitfalls to consider are correct occlusion with the balloon 
and occlusion of the catheter with mucus.
 Greater clinician understanding of and familiarity 
with the Chartis procedure as well as correct interpreta-
tion of the findings are invaluable tools in patient selec-
tion that will further optimize EBV treatment to a highly 
personalized level.
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